Toward target 2035: EUbOPEN - a public-private partnership to enable & unlock biology in the open.
Tredup C., Ackloo S., Beck H., Brown PJ., Bullock AN., Ciulli A., Dikic I., Edfeldt K., Edwards AM., Elkins JM., Farin HF., Fon EA., Gstaiger M., Günther J., Gustavsson A-L., Häberle S., Isigkeit L., Huber KVM., Kotschy A., Krämer O., Leach AR., Marsden BD., Matsui H., Merk D., Montel F., Mulder MPC., Müller S., Owen DR., Proschak E., Röhm S., Stolz A., Sundström M., von Delft F., Willson TM., Arrowsmith CH., Knapp S.
Target 2035 is a global initiative that seeks to identify a pharmacological modulator of most human proteins by the year 2035. As part of an ongoing series of annual updates of this initiative, we summarise here the efforts of the EUbOPEN project whose objectives and results are making a strong contribution to the goals of Target 2035. EUbOPEN is a public-private partnership with four pillars of activity: (1) chemogenomic library collections, (2) chemical probe discovery and technology development for hit-to-lead chemistry, (3) profiling of bioactive compounds in patient-derived disease assays, and (4) collection, storage and dissemination of project-wide data and reagents. The substantial outputs of this programme include a chemogenomic compound library covering one third of the druggable proteome, as well as 100 chemical probes, both profiled in patient derived assays, as well as hundreds of data sets deposited in existing public data repositories and a project-specific data resource for exploring EUbOPEN outputs.